Navigation Links
Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
Date:10/18/2011

TARRYTOWN, N.Y., Oct. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (the "Company") announced the pricing of its offering of $400 million aggregate principal amount of 1.875% convertible senior notes due October 1, 2016.  The notes will be offered by the initial purchaser only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.  The offering is expected to close on October 21, 2011, subject to customary closing conditions.  The Company has also granted to the initial purchaser a 13-day option to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions.

The notes will pay interest semi-annually on April 1 and October 1 at an annual rate of 1.875%, and will mature on October 1, 2016, unless earlier converted or repurchased.  The notes will be convertible, subject to certain conditions, into cash, shares of common stock of the Company, or a combination of cash and shares of common stock, at the Company's option.  The initial conversion rate for the notes will be 11.9021 shares of common stock (subject to adjustment in certain circumstances) per $1,000 principal amount of the notes, which is equal to an initial conversion price of approximately $84.02 per share, representing a conversion premium of approximately 30% above the closing price of the Company's shares of common stock of $64.63 per share on October 17, 2011.

In connection with the offering of the notes, the Company has entered into convertible note hedge and warrant transactions with multiple counterparties, including an affiliate of the initial purchaser (the "option counterparties").  The convertible note hedge transactions cover, subject to customary anti-dilution adjustments, the number of shares of the Company's common stock that initially underlie th
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. Daniel K. ... Michael C. Burgess , M.D., and Joe ... st Century Cures Act, bipartisan legislation in support ... the United States Senate. UT ... department chairs, center directors, and leading researchers – joined ...
(Date:9/1/2015)... , Sept. 1, 2015   Alpha Imaging LLC , a ... Cleveland announced today that they have been awarded exclusive ... imaging systems in Michigan.   The new territory supplements Alpha Imaging,s existing ... including Ohio , Indiana , ... Maryland , West Virginia , ...
(Date:9/1/2015)... Taiwan,s GNT Biotech & Medicals ... Taipei on  August 25 th  to ... drug delivery technology that uses nano-scale gold as the ... a joint press conference held by its parent company ... latest edible gold-based food and beverage partners, together with ...
Breaking Medicine Technology:U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5Alpha Imaging Expands Shimadzu Territory 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5
... NEW DELHI, October 7 DBMS Consulting announced that ... Suite and Oracle E-Business Suite (EBS) for SIRO Clinpharm, ... OHSA offers fully,automated capabilities in management of clinical trial ... After this implementation, SIRO gains ...
... SAN DIEGO and BASKING RIDGE, N.J., Oct. 7 With ... said today from CTIA WIRELESS I.T. & Entertainment 2009® that ... for its Field Force Manager application that helps address the ... become more productive and efficient. , Designed specifically ...
Cached Medicine Technology:DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 2DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 3Verizon Wireless Offers Home Health Care Industry Custom Mobile Application To Be More Productive 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... has announced that Edge Information Management has been granted continued accreditation ... Credentialing Council (BSCC). , “Achieving and maintaining this accreditation takes the ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and analysis of pet vital signs and activity, today announced its integration with ... the most popular and widely-adopted veterinary hospital Practice Management Software packages in the ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and government entities, announced today that it has hired Scott Sanderson, an experienced ... In this capacity, Sanderson will be responsible for establishing and managing new client ...
(Date:9/1/2015)... ... 2015 , ... Royal River Natural Foods, a locally-owned independent natural health store ... 19 years and found that, among those who had a stroke, people who used ... part of the September 2015 issue of “Natural Insights for Well Being,” which Royal ...
(Date:9/1/2015)... ... September 01, 2015 , ... WorkCare, ... has joined its medical management team as an Associate Medical Director. , ... and types in the U.S. and abroad. , Dr. Nelson has a ...
Breaking Medicine News(10 mins):Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
... 2008 (March 24), the Infectious Diseases Society of America ... U.S. policymakers to step up the fight against tuberculosis ... home and abroad. , With drug-resistant strains of TB ... on the decline, resources are needed to support TB ...
... OVERLAND PARK, Kan., March 20 A recent ... a strong reminder to,horse owners throughout the country ... mosquito-borne diseases. To ensure your horse receives,the most ... Nile-,Innovator(R)+EWT -- "The Mosquito Shot," the only vaccine ...
... Experience , KENNEBUNK, Maine, March 20 ... body care, announced a patent-pending breakthrough formula,in its ... Sensitive Care,Toothpastes., (Photo: http://www.newscom.com/cgi-bin/prnh/20080320/NETH004 ), ... cofounder & CEO of Tom,s of Maine, announced ...
... Dreier LLP (http://www.dreierllp.com ),announces that a ... District,Court for the District of Massachusetts on behalf ... the "Company"),(Nasdaq: VRTX ) publicly traded securities ... 2, 2007, inclusive (the "Class Period"). The,Complaint alleges ...
... Mass., March 20 Alseres,Pharmaceuticals, Inc. (Nasdaq: ... a,Third Amended and Restated Convertible Promissory Note Purchase ... L. Gipson, Thomas Gipson, Arthur,Koenig, Ingalls & Snyder ... "Purchaser"). The agreement provides for the Company to ...
... Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) today ... new state-of-the-art global headquarters located at 1781 ... March 31, 2008., The 46,000 square ... and constructed for development and GMP manufacturing,and ...
Cached Medicine News:Health News:ID, HIV experts urge more resources for TB 2Health News:Fort Dodge's 'Mosquito Shot' Offers Convenient Protection Against Dangerous Mosquito-Borne Illnesses 2Health News:Tom's of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes 2Health News:Tom's of Maine Introduces a Patent-Pending New Formula with the Launch of its Natural Clean & Gentle Care and Sensitive Care Toothpastes 3Health News:Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX) 2Health News:Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX) 3Health News:Alseres Pharmaceuticals, Inc. Raises $5 Million 2Health News:Alseres Pharmaceuticals, Inc. Raises $5 Million 3Health News:Response Biomedical Corporation Moves to New Facility 2Health News:Response Biomedical Corporation Moves to New Facility 3Health News:Response Biomedical Corporation Moves to New Facility 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: